-
Bin Chen,
Zhirong Zeng,
Lixia Xu,
Xiaoqin Wu,
Jun Yu,
Ling Xue,
Yuantao Hao,
Yiming Wang,
Joseph J Y Sung,
Minhu Chen,
Pinjin Hu
[show abstract]
[hide abstract]
ABSTRACT: Today, the causal relationship between inflammation and gastric cancer is more widely accepted. Genetic variations in inflammation-related genes especially cytokines and their receptors, were thought to partly determine the outcome of Helicobacter pylori (H. pylori) infection and progression of gastric lesions. Interleukin 23 receptor (IL23R), as a key cytokine receptor gene in the important inflammatory IL-17/IL-23 axis, may contribute to gastric cancer predisposition. Up till now, the associations of IL23R gene polymorphisms with subtypes of gastric cancer are largely unknown.
We investigated whether the association between IL23R +2199 rs10889677 and gastric cancer risk varies by clinical characteristics and the prognostic value of the polymorphism in a case-control study.
A population-based case-control study was conducted in Guangdong. 1010 gastric cancer patients and 800 healthy controls were enrolled. Polymorphism in IL23R was analyzed by PCR-RFLP.
Compared with AA, CC carriers of IL23R +2199 polymorphism were associated with protection against gastric cancer (OR=0.47, 95% CI=0.31-0.71). In stratified analyses, CC genotype was significantly associated with decreased risk of intestinal type (OR=0.44, 95% CI=0.27-0.70), but not with diffuse or mix type of gastric cancer. CC genotype was found to be associated with poorly differentiated (OR=0.43, 95% CI=0.26-0.70), but not with moderately or well differentiated gastric cancer. Multivariate analysis showed IL23R +2199A/C variant was not an independent prognostic factor for gastric cancer patients.
IL23R polymorphism influences certain subtypes of gastric cancer according to clinical and pathological features. Understanding the etiologic heterogeneity of gastric cancer may result in improvements in controlling this disorder.
Cancer epidemiology. 04/2011; 35(2):165-9.
-
[show abstract]
[hide abstract]
ABSTRACT: Chronic inflammation is the hallmark of the pathogenesis of Helicobacter pylori-induced gastric cancer. Interleukin (IL)-17A and IL-17F are inflammatory cytokines expressed by a novel subset of CD4+ Th cells and play critical function in inflammation and probably in cancer. We conducted a case–control study including 1,010 gastric cancer patients and 800 healthy controls to assess the association between IL-17A G197A and IL-17F A7488G polymorphisms and risk of gastric cancer. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing. Logistic regression and Cox-proportional hazards analyses were used to evaluate the associations between polymorphisms and gastric cancer susceptibility, clinicopathological features and survival. After adjusted for age and gender, IL-17F 7488GA and GG genotypes were associated with an increased risk of gastric cancer compared with AA genotype [OR 1.51, 95% confidence interval (CI): 1.22–1.87 for GA; OR 1.61, 95% CI: 1.03–2.51 for GG]. Further stratification analyses indicated that the effect of IL-17F 7488GA genotype was noteworthy in gastric cancer patients of noncardia, intestinal type, poorly and moderately differentiated, age older than 40, large tumor size and lymph node metastasis. IL-17A 197AG genotype was associated with increased risk of poorly differentiated, TNM I/II, age of 40–65-year subtypes of gastric cancer, but not with total gastric cancer risk (p = 0.098). No significant relationship was observed between polymorphisms and survival of gastric cancer patients. These findings suggest that polymorphism of IL-17F 7488 involved in susceptibility to gastric cancer, which also influenced certain subtypes according to clinicopathological features, whereas IL-17A 197 may be less relevant.
International Journal of Cancer 11/2009; 127(1):86 - 92. · 5.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Chronic inflammation is the hallmark of the pathogenesis of Helicobacter pylori-induced gastric cancer. Interleukin (IL)-17A and IL-17F are inflammatory cytokines expressed by a novel subset of CD4+ Th cells and play critical function in inflammation and probably in cancer. We conducted a case-control study including 1,010 gastric cancer patients and 800 healthy controls to assess the association between IL-17A G197A and IL-17F A7488G polymorphisms and risk of gastric cancer. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing. Logistic regression and Cox-proportional hazards analyses were used to evaluate the associations between polymorphisms and gastric cancer susceptibility, clinicopathological features and survival. After adjusted for age and gender, IL-17F 7488GA and GG genotypes were associated with an increased risk of gastric cancer compared with AA genotype [OR 1.51, 95% confidence interval (CI): 1.22-1.87 for GA; OR 1.61, 95% CI: 1.03-2.51 for GG]. Further stratification analyses indicated that the effect of IL-17F 7488GA genotype was noteworthy in gastric cancer patients of noncardia, intestinal type, poorly and moderately differentiated, age older than 40, large tumor size and lymph node metastasis. IL-17A 197AG genotype was associated with increased risk of poorly differentiated, TNM I/II, age of 40-65-year subtypes of gastric cancer, but not with total gastric cancer risk (p = 0.098). No significant relationship was observed between polymorphisms and survival of gastric cancer patients. These findings suggest that polymorphism of IL-17F 7488 involved in susceptibility to gastric cancer, which also influenced certain subtypes according to clinicopathological features, whereas IL-17A 197 may be less relevant.
International Journal of Cancer 11/2009; 127(1):86-92. · 5.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The functional polymorphism of interleukin (IL)-17F 7488 A > G was found to be associated with autoimmune inflammatory diseases and also high IL-17F intestinal expression in inflammatory bowel disease (IBD) was detected. The purpose of this study was to investigate the association between the polymorphism and IBD in the Chinese population and to elucidate potential interactions between IL-17F genotypes and clinical phenotypes.
DNA was extracted from peripheral blood cells of 148 ulcerative colitis (UC), 134 Crohn's disease (CD) patients and 373 age- and gender-matched healthy controls. The IL-17F 7488 A > G polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing.
In UC patients, the homozygous GG genotype frequency was significantly lower than that in the controls (0.0% versus 3.8%, p=0.014); Compared to that of wild-type AA patients, the AG heterozygous carriers have a later onset (43.3+/-11.1 years versus 34.6+/-14.8 years, p = 0.012) and a significantly higher incidence of mild severity (94.1% versus 61.0%, p = 0.009, OR = 0.96, 95% CI = 0.94-0.96), respectively, indicating that subjects with the GG genotype have a slightly decreased risk of 0.96 times for UC compared with that of other genotypes. Further analysis also revealed that G carrier subjects were more likely to present mild severity and had 10.2 times higher incidence of getting mild severity than those with AA genotype (OR = 10.2, 95% CI = 1.3-81.0).
This study shows that IL-17F 7488 A > G polymorphism is associated with weak UC protection in the Chinese population. The clinical phenotypes of UC are also affected by this polymorphism.
Scandinavian journal of gastroenterology 03/2009; 44(6):720-6. · 2.08 Impact Factor
